Aptose Biosciences, headquartered in North York, Ontario, specializes in developing precision anti-cancer therapies, focusing on hematology with two clinical-stage oral kinase inhibitors for hematologic malignancies. The company employs 35 staff and aims to address unmet clinical needs.
Aptose Biosciences (APTOF) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Aptose Biosciences's actual EPS was -$1.34, beating the estimate of -$10.71 per share, resulting in a 87.52% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
